Intermountain Healthcare | Strategic Alliance Partners

Latest from Intermountain Healthcare

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

December 24th 2024

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Ramya Thota, MBBS, FASCO, Intermountain Medical Oncology

ASCO Issues Statement Calling for Streamlined Clinical Trial Requirements

ByKyle Doherty

August 14th 2024

ASCO has released a research statement outlining 4 recommendations to decentralize clinical trials and improve patient access to these studies.

Intermountain Healthcare | Strategic Alliance Partners

Latest from Intermountain Healthcare

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

ASCO Issues Statement Calling for Streamlined Clinical Trial Requirements

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Oncology Fellows Highlights 2025 ESMO Fellowship Winners

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL